Health Dictionary Find a Doctor

Human ehrlichiosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information, click here

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Electronphotomicrograph of morulae in a bone marrow leukocyte in a patient with ehrlichiosis. Arrows indicate individual ehrlichiae.

Toward the end of the 19th century, scientists began to understand the important potential for ticks to act as transmitters of disease. In the last decades of the 20th century, several tick-borne diseases have been recognized in the United States, including babesiosis, Lyme disease, and ehrlichiosis.

Ehrlichiosis is caused by several bacterial species in the genus Ehrlichia (pronounced err-lick-ee-uh) which have been recognized since 1935. Over several decades, veterinary pathogens that caused disease in dogs, cattle, sheep, goats, and horses were identified. Currently, three species of Ehrlichia in the United States and one in Japan are known to cause disease in humans; others could be recognized in the future as methods of detection improve.

In 1953, the first ehrlichial pathogen of humans was identified in Japan. Sennetsu fever, caused by Ehrlichia sennetsu, is characterized by fever and swollen lymph nodes. The disease is very rare outside the Far East and Southeast Asia, and most cases have been reported from western Japan.

In the United States, human diseases caused by Ehrlichia species have been recognized since the mid-1980s. The ehrlichioses represent a group of clinically similar, yet epidemiologically and etiologically distinct, diseases caused by Ehrlichia chaffeensis, E. ewingii, and a bacterium extremely similar or identical to E. phagocytophila. The remainder of the information on this web page will focus on the types of ehrlichiosis that occur in the United States.

Human ehrlichiosis due to Ehrlichia chaffeensis was first described in 1987. The disease occurs primarily in the southeastern and south central regions of the country and is primarily transmitted by the lone star tick, Amblyomma americanum.

Human granulocytic ehrlichiosis (HGE) represents the second recognized ehrlichial infection of humans in the United States, and was first described in 1994. The name for the species that causes HGE has not been formally proposed, but this species is closely related or identical to the veterinary pathogens Ehrlichia equi and Ehrlichia phagocytophila. HGE is transmitted by the blacklegged tick (Ixodes scapularis) and the western blacklegged tick (Ixodes pacificus) in the United States.

Ehrlichia ewingii is the most recently recognized human pathogen. Disease caused by E. ewingii has been limited to a few patients in Missouri, Oklahoma, and Tennessee, most of whom have had underlying immunosuppression. The full extent of the geographic range of this species, its vectors, and its role in human disease is currently under investigation.

History and Symptoms

The early clinical presentations of ehrlichiosis may resemble nonspecific signs and symptoms of various other infectious and non-infectious diseases. It is unclear if all persons infected with ehrlichiae become ill. It is possible that many infected persons develop an illness so mild they do not seek medical attention or perhaps have no symptoms at all.

Laboratory Findings

A diagnosis of ehrlichiosis is based on a combination of clinical signs and symptoms and confirmatory laboratory tests. Your doctor can send your blood sample to a reference laboratory for testing. However, the availability of the different types of laboratory tests varies considerably. Other laboratory findings indicative of ehrlichiosis include low white blood cell count, low platelet count, and elevated liver enzymes.

Medical Therapy

Appropriate antibiotic treatment should be initiated immediately when there is a strong suspicion of ehrlichiosis on the basis of clinical and epidemiologic findings. Treatment should not be delayed until laboratory confirmation is obtained. Fever generally subsides within 24-72 hours after treatment with doxycycline or other tetracyclines. In fact, failure to rapidly respond to a tetracycline antibiotic argues against a diagnosis of ehrlichiosis. Preventative therapy in non-ill patients who have had recent tick bites is not warranted.

Prevention

Limiting exposure to ticks reduces the likelihood of ehrlichial infection. In persons exposed to tick-infested habitats, prompt careful inspection and removal of crawling or attached ticks is an important method of preventing disease. It may take several hours of attachment before microorganisms are transmitted from the tick to the host.

References

Template:WH Template:WS

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Pathophysiology

Ehrlichiae are small, gram-negative bacteria that primarily invade leukocytes (white blood cells), the same cells which fight disease by destroying microorganisms that enter the body. Ehrlichiae typically appear as minute, round bacteria (cocci), ranging from 1 to 3 µm (micrometers) in diameter. In the leukocytes, ehrlichiae divide to form vacuole-bound colonies known as morulae (plural for morula, which is the Latin word for mulberry, referring to the mulberry-like clustering of the dividing organisms). The formation of morulae is a defining characteristic of this group of bacterial pathogens (Figure A).

Taxonomy

The genus Ehrlichia is currently classified as a member of the tribe Ehrlichieae, of the family Rickettsiaceae, in the order Rickettsiales. The genus includes seven recognized species: E. canis, E. chaffeensis, E. equi, E. phagocytophila, E. risticii, E. ewingii, and E. sennetsu. A number of other named ehrlichiae, such as E. platys, E. bovis, E. ovina, and E. ondiri also cause disease in animals (Table 1). The names of the latter organisms are enclosed in quotation marks because they have not been formally proposed and accepted according to the rules of the International Code of Nomenclature of Bacteria, Bacteriological Code.

The ehrlichiae were initially grouped according to the type of blood cell most commonly infected (granulocyte, lymphocyte, monocyte, platelet), and disease classes have been termed “granulocytic (or granulocytotropic) ehrlichiosis” or “monocytic (or monocytotropic) ehrlichiosis.” However, this type of classification may be misleading because some of the Ehrlichia species have been found in cells other than their chief target cell type. In addition, more than one species may be responsible for the broad category of “monocytic” or “granulocytic” ehrlichiosis (e.g., compare the HGE agent and E. ewingii in the figures below).

  • Figure B. Ehrlichia chaffeensis primarily infects mononuclear leukocytes (predominantly monocytes and macrophages), but may also be seen occasionally in the granulocytes of some patients with severe disease.
  • Figure C. The pathogen that causes human granulocytic ehrlichiosis (HGE) primarily infects granulocytes (neutrophils and rarely eosinophils). The pathogen is often referred to as the agent of HGE or the HGE agent. This species is very similar, or likely identical, to E. phagocytophila and E. equi.
  • Figure D. Ehrlichia ewingii primarily infects neutrophils and occasionally eosinophils and produces a disease clinically similar to HME and HGE. Most patients with this form of ehrlichiosis have also had other medical conditions causing immunosuppression (e.g., HIV infection, splenectomy, transplantation, immunosuppressive drugs).

Modern Classification

Using modern molecular biology techniques, we now know that Ehrlichia species form three distinct groups (see Figure 5 below). The species contained within these “genogroups” are also related to organisms not previously considered to be members of this genus. The classification of the genus Ehrlichia requires revision, and future studies may provide the additional data needed.

  • Figure D. Genetic relationship of Ehrlichia species and other bacteria based on similarity of 16rRNA gene
Figure D. Genetic relationship of Ehrlichia species and other bacteria based on similarity of 16rRNA gene
Figure D. Genetic relationship of Ehrlichia species and other bacteria based on similarity of 16rRNA gene


References

Template:WH Template:WS

Causes

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

References

Template:WH Template:WS

Differentiating Human ehrlichiosis from other Diseases

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

References

Template:WH Template:WS

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Epidemiology and Demographics

United States

During 1986 to 1997, health departments and other diagnostic laboratories reported over 1200 cases of human ehrlichiosis to CDC. Approximately two-thirds were cases of HME. CDC compiles the number of cases reported by the state health departments. Ehrlichiosis is a nationally notifiable disease; however, not all state health departments have reported cases of ehrlichiosis to CDC (Figure 1). To ensure standardization across the country, a consistent case definition is used by all states when reporting cases to CDC.

  • Figure 1: Reported Cases of Ehrlichiosis in the United States
Reported Cases of Ehrlichiosis in the United States


The occurrence of these diseases mirrors the geographic distributions and seasonal activities of the tick vectors. Most patients with ehrlichiosis are infected in the spring and summer when they are more commonly exposed to vector ticks. Accordingly, 80% to 90% of all ehrlichiosis cases occur between April and September, and approximately 55% to 70% of all cases occur during May through July (Figure 2). This period is the season for adult Amblyomma americanum and nymphal Ixodes scapularis ticks. A history of tick bite or exposure to tick-infested habitats is reported in 50% to 90% of cases.

  • Figure 2: Approximate seasonal distribution of HGE in the United States
Approximate seasonal distribution of HGE in the United States


Ehrlichia chaffeensis infections are most frequently reported from southeastern and midwestern states with abundant lone star tick populations, especially Arkansas, Florida, Georgia, Missouri, North Carolina, Oklahoma, Tennessee, Texas, and Virginia. Cases have been reported from almost every state in the United States, although some of these may have been imported from states where the disease is highly endemic.

The types of ehrlichiosis are distinct from several other well-described tick-transmitted diseases in the United States with respect to age-specific incidence (Figure 3). In general, reported rates of ehrlichiosis increase with age; most patients with disease appear to be older adults (most often >40 years old). This pattern contrasts with age-specific incidences of Lyme disease and Rocky Mountain spotted fever, which occur most frequently in children. Age-associated host factors may account for severity of disease; however, severe and even fatal ehrlichial infections have occurred in otherwise healthy young adults and children.

  • Figure 3: Average annual reported HGE rate (per 100,000) by age group, in NY and CT, 1995-1997
Average annual reported HGE rate (per 100,000) by age group, in NY and CT, 1995-1997


Most of the recognized HGE cases have originated from states that also have a high incidence of Lyme disease, particularly Connecticut, Minnesota, New York, and Wisconsin. This distribution is consistent with the fact that the vector of HGE, Ixodes scapularis, also transmits Borrelia burgdorferi. A number of other states have also reported HGE cases. In the western United States, the HGE agent is transmitted by the western blacklegged tick, Ixodes pacificus (Figure 4).

  • Figure 4: Areas where human ehrlichiosis may occur based on approximate distribution of vector tick species
Areas where human ehrlichiosis may occur based on approximate distribution of vector tick species


Relatively few population-based investigations have pursued the fundamental question of how many persons become ill after infection with ehrlichiae. A study conducted in southeastern Georgia during 1987-1988 examined the incidence of E. chaffeensis infection among hospitalized patients with fever and determined an incidence of 5.3 cases per 100,000 total population per year. Passive surveillance data for these infections are also sparse, and are collected from relatively few regions of the United States where Ehrlichia species are endemic.

As of 1999, cases of ehrlichiosis must be reported to the state health department in at least 20 states (Alabama, Arkansas, Arizona, California, Connecticut, Delaware, Florida, Georgia, Kentucky, Maine, Michigan, Minnesota, Missouri, Montana, New Jersey, New Hampshire, New York, North Carolina, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, and Utah) (Figure 5).

  • Figure 5: States where Ehrlichiosis is a notifiable disease
States where Ehrlichiosis is a notifiable disease


Data from statewide laboratory-based surveillance initiated by New York in 1994 and by Connecticut in 1995 revealed annual reporting rates of ehrlichiosis of 0.4 and 1.8 cases per 100,000 persons, respectively. Foci of disease have been identified in defined geographical regions with reported annual rates as high as 16 cases per 100,000 persons for HGE and 31 cases per 100,000 persons for HME infection.

Worldwide

Ehrlichial pathogens are distributed globally, primarily in temperate regions. Patients with serologic evidence of infection with E. chaffeensis or, more likely, with a species antigenically related to E. chaffeensis have been identified in several other countries, including Argentina, Belgium, Israel, Italy, Mali, Mexico, Portugal, and Thailand. Similarly, human infections with E. phagocytophila have been confirmed in Belgium, Denmark, Hungary, Slovenia, and Sweden, and persons with antibodies reactive to granulocytic ehrlichiae have been identified in Germany, Israel, Italy, Norway, Switzerland, and the United Kingdom.

References

Template:WH Template:WS

Risk Factors

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

References

Template:WH Template:WS

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.

Natural History

Studies throughout the world have shown that many cases of human illness are caused by zoonotic pathogens that are maintained by animal hosts in their natural cycles. Many zoonoses require a vector (e.g., mosquito, tick, mite) to be transmitted from the animal host to the human host. The ehrlichial disease cycle includes four components: the pathogen, the animal reservoir species, the vectors, and the human host. For the types of human ehrlichiosis in the United States, the arthropod vectors are ticks.

Only one of the three tick families, Ixodidae (hard ticks), is associated with ehrlichiae. These ticks have four stages in their life cycle: egg, larva, nymph, and adult. After the eggs hatch, each stage must feed once to develop into the next stage. Larvae are uninfected with ehrlichiae when they begin to look for a blood-meal. Ticks become infected with ehrlichiae while feeding on blood from the host in either the larval or nymphal stage. After the tick develops into the next stage, the ehrlichiae may be transmitted to the following host during the feeding process. Both male and female ticks may bite humans but it is the females that are responsible for most transmission. In the United States, it appears that both the nymphal and adult stages are responsible for transmission of ehrlichiae, but one stage may be more important for each Ehrlichia species.

Can A Person Get Ehrlichiosis More Than Once?

Very little is known about immunity to ehrlichial infections. Although it has been proposed that infection with ehrlichiae confers long-term protection against reinfection, there have been occassional reports of laboratory-confirmed reinfection. Short-term protection has been described in animals infected with some Ehrlichia species and this protection wanes after about 1 year. Clearly, more studies are needed to determine the extent and duration of protection against reinfection in humans.

References

Template:WH Template:WS

Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

External Links
  1. http://www.cdc.gov/ncidod/dvrd/ehrlichia/Index.htm
Acknowledgements

Acknowledgements

The content on this page was first contributed by: C. Michael Gibson, M.S., M.D.


Template:WH Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH